Investment Analysts’ Recent Ratings Changes for Context Therapeutics (CNTX)

Several brokerages have updated their recommendations and price targets on shares of Context Therapeutics (NASDAQ: CNTX) in the last few weeks:

• 3/29/2026 – Context Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/24/2026 – Context Therapeutics had its “buy” rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.
• 3/24/2026 – Context Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.
• 3/24/2026 – Context Therapeutics had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an “overweight” rating on the stock.
• 3/21/2026 – Context Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/28/2026 – Context Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/23/2026 – Context Therapeutics was upgraded by Lifesci Capital to “strong-buy”.
• 2/16/2026 – Context Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/8/2026 – Context Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 1/31/2026 – Context Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.